4.5 Article

Cholinergic Targets in Lung Cancer

Journal

CURRENT PHARMACEUTICAL DESIGN
Volume 22, Issue 14, Pages 2152-2159

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612822666160127114237

Keywords

Cancer; acetylcholine; nicotine; nicotinic receptors; muscarinic receptors; lynx-1

Funding

  1. NIH [CA151601, HL087710, OD011092]

Ask authors/readers for more resources

Lung cancers express an autocrine cholinergic loop in which secreted acetylcholine can stimulate tumor growth through both nicotinic and muscarinic receptors. Because activation of mAChR and nAChR stimulates growth; tumor growth can be stimulated by both locally synthesized acetylcholine as well as acetylcholine from distal sources and from nicotine in the high percentage of lung cancer patients who are smokers. The stimulation of lung cancer growth by cholinergic agonists offers many potential new targets for lung cancer therapy. Cholinergic signaling can be targeted at the level of choline transport; acetylcholine synthesis, secretion and degradation; and nicotinic and muscarinic receptors. In addition, the newly describe family of ly-6 allosteric modulators of nicotinic signaling such as lynx1 and lynx2 offers yet another new approach to novel lung cancer therapeutics. Each of these targets has their potential advantages and disadvantages for the development of new lung cancer therapies which are discussed in this review.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available